Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications

Journal: Science

Published: 2020-09-04

DOI: 10.1126/science.abc8511

Affiliations: 15

Authors: 39

Go to article
Institutions Share
Penn Institute for Immunology, United States of America (USA) 0.37
Department of Systems Pharmacology and Translational Therapeutics, Penn, United States of America (USA) 0.18
Department of Microbiology, Penn, United States of America (USA) 0.13
Penn-CHOP Lung Biology Institute, United States of America (USA) 0.08
Parker Institute for Cancer Immunotherapy, United States of America (USA) 0.04
Department of Pathology and Laboratory Medicine, Penn, United States of America (USA) 0.04
Center for Cellular Immunotherapies (CCI), Penn, United States of America (USA) 0.04
Division of Translational Medicine and Human Genetics, Penn Medicine, United States of America (USA) 0.03
Department of Microbiology and Immunology, TJU, United States of America (USA) 0.03
Division of Pulmonology, Allergy, Immunology and Critical Care, Penn Medicine, United States of America (USA) 0.03
Division of Gastroenterology (GI), Penn Medicine, United States of America (USA) 0.01
Division of Rheumatology, Penn Medicine, United States of America (USA) 0.01
Division of Hematology and Oncology, Penn Medicine, United States of America (USA) 0.01
Division of Infectious Diseases, CHOP, United States of America (USA) 0.01
Department of Pediatrics, CHOP, United States of America (USA) 0.01

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER